Inhibikase Therapeutics, Inc.
IKT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $225 | $7 | $13 | $27 |
| - Cash | $56 | $9 | $7 | $41 |
| + Debt | $0 | $1 | $0 | $0 |
| Enterprise Value | $169 | -$2 | $6 | -$14 |
| Revenue | $0 | $0 | $0 | $3 |
| % Growth | -100% | 111% | -96% | – |
| Gross Profit | -$0 | -$13 | $0 | -$8 |
| % Margin | – | -5,127.8% | 94.6% | -266.4% |
| EBITDA | -$27 | -$20 | -$18 | $0 |
| % Margin | – | -7,643.9% | -14,620.4% | 0% |
| Net Income | -$28 | -$19 | -$18 | -$15 |
| % Margin | – | -7,304.8% | -14,625.9% | -476.9% |
| EPS Diluted | -1.16 | -3.57 | -4.26 | -4.88 |
| % Growth | 67.5% | 16.2% | 12.7% | – |
| Operating Cash Flow | -$19 | -$18 | -$17 | -$14 |
| Capital Expenditures | $0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$19 | -$18 | -$18 | -$14 |